173 related articles for article (PubMed ID: 17207192)
1. Major oral aphtous ulceration in HIV-1 infection: successful response after highly active antiretroviral therapy.
Dalmau J; Alegre M; Domingo P; Alomar A
J Eur Acad Dermatol Venereol; 2007 Jan; 21(1):126-7. PubMed ID: 17207192
[No Abstract] [Full Text] [Related]
2. Successful treatment of major oral aphthous ulcers in HIV-1 infection after highly active antiretroviral therapy.
Alegre M; Dalmau J; Domingo P; Roé E; Alomar A
Int J Infect Dis; 2007 May; 11(3):278-9. PubMed ID: 16857406
[No Abstract] [Full Text] [Related]
3. [Pentoxifylline and oral aphthosis in patients with HIV infection].
Blanch Falp J; García Pont X; Torne Cachot J; Moner Coromina L; Baucells Azcona JM
An Med Interna; 1997 Feb; 14(2):102. PubMed ID: 9206506
[No Abstract] [Full Text] [Related]
4. [Steroid therapy of non-specific aphthous ulcers in patients with HIV infection].
López-Gómez M; Hernández Burruezo JJ; Castaño J; Gea I; Mateas Ruiz F
An Med Interna; 1993 May; 10(5):258-9. PubMed ID: 8518346
[No Abstract] [Full Text] [Related]
5. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
[TBL] [Abstract][Full Text] [Related]
6. Bacterial community acquired pneumonia in HIV-infected inpatients in the highly active antiretroviral therapy era.
Madeddu G; Porqueddu EM; Cambosu F; Saba F; Fois AG; Pirina P; Mura MS
Infection; 2008 Jun; 36(3):231-6. PubMed ID: 18463787
[TBL] [Abstract][Full Text] [Related]
7. Impact of PI and NNRTI HAART-based therapy on oral lesions of Brazilian HIV-infected patients.
Ortega KL; Vale DA; Magalhães MH
J Oral Pathol Med; 2009 Jul; 38(6):489-94. PubMed ID: 19453845
[TBL] [Abstract][Full Text] [Related]
8. The intestinal mucosa as a reservoir of HIV-1 infection after successful HAART.
Belmonte L; Olmos M; Fanin A; Parodi C; Baré P; Concetti H; Pérez H; de Bracco MM; Cahn P
AIDS; 2007 Oct; 21(15):2106-8. PubMed ID: 17885303
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment of acute myeloradiculoneuritis with high-dose corticosteroids in a patient with primary HIV-1 infection.
Yasuoka C; Kikuchi Y; Yasuoka A; Yamaguchi M; Yamamoto Y; Genka I; Teruya K; Tachikawa N; Shimpo T; Oka S
Jpn J Infect Dis; 2000 Aug; 53(4):171-2. PubMed ID: 11056563
[No Abstract] [Full Text] [Related]
10. Thalidomide in oral aphthous ulceration in patients with HIV infection.
Henriquet F; Roy MT; Repetto T; Fusco F
Palliat Med; 1994; 8(3):255-6. PubMed ID: 7952375
[No Abstract] [Full Text] [Related]
11. Major aphthous-like ulcers in two patients infected with human immunodeficiency virus.
Livingston W; Stevens AW; Phelan J; Gregory N; Grossman ME
Cutis; 1997 May; 59(5):281-3. PubMed ID: 9169272
[TBL] [Abstract][Full Text] [Related]
12. Regression of Kaposi's sarcoma lesions following highly active antiretroviral therapy in an HIV-infected patient.
Kumarasamy N; Venkatesh KK; Devaleenol B; Poongulali S; Ahilasamy N
Int J STD AIDS; 2008 Nov; 19(11):786-8. PubMed ID: 18931277
[TBL] [Abstract][Full Text] [Related]
13. Thalidomide for severe aphthous ulceration in patients with human immunodeficiency virus (HIV) infection.
Oldfield EC
Am J Gastroenterol; 1994 Dec; 89(12):2276-7. PubMed ID: 7977265
[No Abstract] [Full Text] [Related]
14. Trends in bacteremia in the pre- and post-highly active antiretroviral therapy era among HIV-infected children in the US Perinatal AIDS Collaborative Transmission Study (1986-2004).
Kapogiannis BG; Soe MM; Nesheim SR; Sullivan KM; Abrams E; Farley J; Palumbo P; Koenig LJ; Bulterys M
Pediatrics; 2008 May; 121(5):e1229-39. PubMed ID: 18450865
[TBL] [Abstract][Full Text] [Related]
15. Behçet's disease in an HIV-1-infected patient treated with highly active antiretroviral therapy.
Gómez-Puerta JA; Espinosa G; Miró JM; Sued O; Llibre JM; Cervera R; Font J
Isr Med Assoc J; 2006 Jul; 8(7):513-4. PubMed ID: 16889175
[No Abstract] [Full Text] [Related]
16. Effect of highly active antiretroviral therapy on ischemic cardiovascular disease in patients with HIV-1 infection.
Torre D; Pugliese A; Orofino G
Clin Infect Dis; 2002 Sep; 35(5):631-2. PubMed ID: 12173141
[No Abstract] [Full Text] [Related]
17. Comparison of first antiretroviral treatment duration and outcome in HIV, HIV-HBV and HIV-HCV infection.
Cooper CL; Mills E
Int J STD AIDS; 2007 Aug; 18(8):546-50. PubMed ID: 17686217
[TBL] [Abstract][Full Text] [Related]
18. Impact of hepatitis B virus co-infection on response to highly active antiretroviral treatment and outcome in HIV-infected individuals: a nationwide cohort study.
Omland LH; Weis N; Skinhøj P; Laursen A; Christensen PB; Nielsen HI; Møller A; Engsig F; Sørensen HT; Obel N
HIV Med; 2008 May; 9(5):300-6. PubMed ID: 18400077
[TBL] [Abstract][Full Text] [Related]
19. Superior virological response to boosted protease inhibitor-based highly active antiretroviral therapy in an observational treatment programme.
Wood E; Hogg RS; Yip B; Moore D; Harrigan PR; Montaner JS
HIV Med; 2007 Mar; 8(2):80-5. PubMed ID: 17352763
[TBL] [Abstract][Full Text] [Related]
20. Neurodevelopmental functioning in HIV-infected infants and young children before and after the introduction of protease inhibitor-based highly active antiretroviral therapy.
Lindsey JC; Malee KM; Brouwers P; Hughes MD;
Pediatrics; 2007 Mar; 119(3):e681-93. PubMed ID: 17296781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
